Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Coronary Syndrome
- Dyslipidemias
- Hypercholesterolemia
- Hyperlipidemias
- Physiological Effects of Drugs
- ST Elevation Myocardial Infarction
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: A randomized, double-blind, sham-controlled parallel group clinical trial.Masking: Triple (Participant, Investigator, Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03718286
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Shamir Mehta, MD MSc FRCPC Population Health Research Institute; McMaster University